Search
Young EHA
Welcome to Young EHA!As a junior member of EHA, you are part of the Young EHA family.
Read moreMeet Ton Hagenbeek, our May volunteer of the month
Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.
Read moreMeet Ton Hagenbeek, our May volunteer of the month
Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.
Read moreMeet Michaela Gruber, our December volunteer of the month
Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.
Meet Michaela Gruber, our December volunteer of the month
Can you tell us what you do for EHA and when you started?
Over six years ago, I was one of the initiators of what is now the “YoungEHA” and the “Young-EHA Committee”.
Introducing YoungEHA: you don’t have to grow old to make a difference
By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee. Hearing exciting new research, attending lectures by leaders in the field, and networking are some of the obvious things that are happening during the annual EHA congress.
Read moreEHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma
EHA and ESMO agreed to collaborate in the production of European Guidelines for different hematological malignancies. For the second workshop in the series participants joined us for the EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma.
Read moreHighlights of Past EHA (HOPE) Asia 2021
For the third edition of the Highlights of Past EHA (HOPE) Asia, EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.
Read moreCurrent status of the Clinical Trials Regulation
HemAffairs Article #2 – June 2019
In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable.
Pivotal Ruxolitinib Data Shows Promise for Patients with PV.
Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.